Pharm Exec6d
Jelmyto Demonstrates Significant Recurrence-Free Survival Rate at Three Years in Patients with Low-Grade Upper Tract Urothelial Cancer
Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with ...
JELMYTO shows promise in long-term cancer treatment study
PRINCETON, N.J. - Recent findings from a study on UroGen Pharma Ltd.'s (NASDAQ: URGN) JELMYTO (mitomycin) for pyelocalyceal solution suggest its effectiveness in long-term disease control for patients ...
Business Wire8d
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper ...
The long-term study evaluated 56 patients who achieved complete response after treatment with JELMYTO from 15 high-volume academic and community centers and helps characterize how urologists are ...
UroGen Pharma Reveals Promising Developments in Latest 8-K Filing
UroGen Pharma Ltd., a pioneering pharmaceutical company with a focus on innovative treatments for urothelial cancers, recently submitted an 8-K form to the Securities and Exchange Commission, ...
Investing8d
JELMYTO shows promise in long-term cancer treatment study
PRINCETON, N.J. - Recent findings from a study on UroGen Pharma Ltd.'s (NASDAQ: URGN) JELMYTO (mitomycin) for pyelocalyceal solution suggest its effectiveness in long-term disease control for ...